Summarized by Masters of Longevity from Apollo Health Ventures.
The company raised $65 million to advance RNA-guided therapies for chronic and age-related diseases, including its heart-failure candidate HTX-001.
Key Takeaways
- Sofinnova Partners and Earlybird Venture Capital led the financing.
- Proceeds support HTX-001 heart-failure trials and expansion of the RNA-guided pipeline.
- HTX-001 remained investigational; the announcement did not establish clinical benefit.
